News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ex-Geron Corporation (GERN) CEO Launches Effort to Revive Lost Stem Cell Program



10/25/2012 9:07:17 AM

The world's largest embryonic stem cell research programme could be given a new lease of life. In 2011, biotech giant Geron announced that it was closing its stem cell programme, even though it had conducted a decade of research and treated four people in the first clinical trial of human embryonic stem cells (hESCs). Now, Geron's former chief executive Thomas Okarma, and founder Michael West, have joined forces with a new subsidiary of BioTime, a biotech company based in Alameda, California. Together they have put forward a bid for Geron's stem cell assets in an effort to revive the programme. Meanwhile, the four volunteers that received hESCs for spinal injuries are being monitored for adverse effects by the California Institute for Regenerative Medicine in San Francisco.

Read at New Scientist


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES